Birgand Gabriel, Radu Costin, Alkhoder Soleiman, Al Attar Nawwar, Raffoul Richard, Dilly Marie-Pierre, Nataf Patrick, Lucet Jean-Christophe
Infection Control Unit, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Interact Cardiovasc Thorac Surg. 2013 Feb;16(2):134-41. doi: 10.1093/icvts/ivs449. Epub 2012 Oct 31.
Sternal wound infections occurring after cardiac surgery have a critical impact on morbidity, mortality and hospital costs. This study evaluated the efficacy of a gentamicin-collagen sponge in decreasing deep sternal-wound infections in high-risk cardiac surgery patients.
We conducted a quasi-experimental single-centre prospective cohort study in diabetic and/or overweight patients undergoing coronary-artery bypass surgery with bilateral internal mammary artery grafts. The end-point was the rate of reoperation for deep sternal wound infection. The period from January 2006 to October 2008, before the introduction of the gentamicin sponge, was compared with the period from November 2008 to December 2010.
Of 552 patients (median body mass index, 31.5; 37.7% with diabetes requiring insulin), 68 (12.3%) had deep sternal wound infections. Reoperation for deep sternal wound infections occurred in 40/289 (13.8%) preintervention patients and 22/175 (12.6%) patients managed with the sponge. Independent risk factors were female sex and longer time on mechanical ventilation, but not use of the sponge (adjusted odds ratio, 0.95; 95% confidence interval, 0.52-1.73; P = 0.88). The group managed with the sponge had a higher proportion of gentamicin-resistant micro-organisms (21/27, 77.8%) compared with the other patients (23/56, 41.1%; P < 0.01). The median time to reoperation for wound infection was higher with the sponge (21 vs 17 days, P < 0.01).
A gentamicin-collagen sponge was not effective in preventing deep sternal wound infections in high-risk patients. Our results suggest that a substantial proportion of wound contaminations occur after bypass surgery with bilateral internal mammary artery grafts.
心脏手术后发生的胸骨伤口感染对发病率、死亡率和医院成本有重大影响。本研究评估庆大霉素 - 胶原海绵在降低高危心脏手术患者深部胸骨伤口感染方面的疗效。
我们对接受双侧乳内动脉搭桥冠状动脉旁路移植术的糖尿病和/或超重患者进行了一项单中心前瞻性队列准实验研究。终点是深部胸骨伤口感染的再次手术率。将2006年1月至2008年10月(引入庆大霉素海绵之前)的时间段与2008年11月至2010年12月的时间段进行比较。
在552例患者中(中位体重指数为31.5;37.7%的患者患有需要胰岛素治疗的糖尿病),68例(12.3%)发生了深部胸骨伤口感染。在干预前的289例患者中有40例(13.8%)因深部胸骨伤口感染进行了再次手术,而使用海绵治疗的175例患者中有22例(12.6%)进行了再次手术。独立危险因素为女性和机械通气时间较长,但与是否使用海绵无关(调整后的比值比为0.95;95%置信区间为0.52 - 1.73;P = 0.88)。与其他患者相比,使用海绵治疗的组中耐庆大霉素微生物的比例更高(21/27,77.8%)(23/56,41.1%;P < 0.01)。使用海绵时伤口感染再次手术的中位时间更长(21天对17天,P < 0.01)。
庆大霉素 - 胶原海绵在预防高危患者深部胸骨伤口感染方面无效。我们的结果表明,在双侧乳内动脉搭桥的旁路手术后,相当一部分伤口发生了污染。